Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Pilot Study in AIDS-Related Lymphomas
NCT00002524CI-TRIAL-00007616completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (18)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bleomycin Sulfate | Biological | Bleomycin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Doxorubicin Hydrochloride (DOX) | Drug | Doxorubicin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Filgrastim | Biological | Filgrastim | ALIAS |
| Fluorouracil | Drug | Fluorouracil | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Regimen A
- description
- Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.
- interventionNames
- Biological: Bleomycin Sulfate
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride (DOX)
- Drug: Pentamidine
- Drug: Prednisone
- Drug: Trimethoprim-Sulfamethoxazole
- Drug: Vincristine Sulfate
- Drug: Zidovudine (AZT)
- Radiation: Radiation Therapy
- type
- EXPERIMENTAL
- label
- Regimen B
- description
- Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy
- interventionNames
- Biological: Filgrastim
- Drug: Cytarabine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: Previously untreated, HIV-related intermediate- and high-grade lymphoma with no previous diagnosis of Kaposi's sarcoma Pathology reviewed at M.D. Anderson Cancer Center PATIENT CHARACTERISTICS: Age: Over 15 Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: For patients with T4 less than 200 and those with primary brain lymphoma: Creatinine no greater than 2.0 mg/dL (unless entry approved by principal investigator) Other: Serious intercurrent illness must be discussed with the principal investigator Infectious disease consultation required for complex infections Medications for other conditions allowed provided no adverse interaction with protocol therapy occurs No previously diagnosed Kaposi's sarcoma or other malignancy PRIOR CONCURRENT THERAPY: No prior therapy for lymphoma No concurrent chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.